Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension

• Published in: The American heart journal Vol. 121; no. 1 Pt 2; p. 356
• Main Authors: Monsalve, P, Vera, O, Pérez Acuña, F, Medina, O, Ostojich, K, López, B, Torres, N, Lugo de Franco, V, Fonseca, R
• Format: Journal Article
• Language: English
• Published: United States 01-01-1991
• Subjects: Antihypertensive Agents - therapeutic use; Cardiomegaly - diagnostic imaging; Cardiomegaly - drug therapy; Cholesterol - blood; Coronary Disease - epidemiology; Doxazosin; Echocardiography; Female; Humans; Hypertension - drug therapy; Lipids - blood; Male; Middle Aged; Prazosin - analogs & derivatives; Prazosin - therapeutic use; Risk Factors; Venezuela - epidemiology
• ISSN: 0002-8703
• DOI: 10.1016/0002-8703(91)90872-f

A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension. The systolic shortening coefficient was also increased and a trend in the improvement of ejection fraction, rate of circumferential fiber shortening, systolic contraction time, and preejective/ejective ratio was observed. No change in heart rate was recorded and no patients had side effects. The serum lipid profile was modified favorably, particularly with regard to the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio. By producing a reduction in blood pressure and left ventricular mass while favorably modifying the serum lipid profile, doxazosin produced a beneficial change in the overall coronary heart disease risk profile.